Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma

Share this content:
Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma
Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma

Amgen has announced a collaboration with Janssen Biotech Inc to assess the combination of carfilzomib (Kyprolis) with daratumumab (Darzalex) in numerous clinical trials in patients with multiple myeloma.1

The first study that will be conducted as part of this agreement is an open-label, phase 3 registrational trial evaluating the combination of carfilzomib, daratumumab, and dexamethasone compared with carfilzomib plus dexamethasone alone in patients with multiple myeloma who have received 1 to 3 prior lines of treatment.

In the first arm, patients will receive carfilzomib 56 mg/m2 IV twice weekly plus dexamethasone in combination with daratumumab (KdD) until disease progression or unacceptable toxicity. Patients in the control arm will receive the same dose of carfilzomib. The primary end point is progression-free survival and secondary end points include overall response rate, minimal residual disease, and overall survival.

"Given the relapsing nature of multiple myeloma, several options are needed to attack the disease differently and keep patients in remission as long as possible," Sean E. Harper, MD, executive vice president of Research and Development at Amgen, said in a press release. "We are excited to collaborate with Janssen to evaluate the potential of combining Kyprolis, a powerful proteasome inhibitor (PI), with Darzalex, the first human anti-CD38 monoclonal antibody for the treatment of multiple myeloma in the relapsed setting."

Daratumumab is indicated for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. Carfilzomib is currently approved as a single-agent and in combination with dexamethasone with or without lenalidomide for patients with relapsed or refractory multiple myeloma.


1. Amgen announces collaboration with Janssen to co-fund studies with Kyprolis (carfilzomib) and Darzalex (daratumumab) in patients with multiple myeloma. Amgen website. http://www.amgen.com/media/news-releases/2016/11/amgen-announces-collaboration-with-janssen-to-cofund-studies-with-kyprolis-carfilzomib-and-darzalex-daratumumab-in-patients-with-multiple-myeloma/. Updated November 10, 2016. Accessed November 10, 2016.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs